Targeted therapies for the myeloid leukaemias

Bibliography

• WARRELL RP JR., DE THE H, WANG Z-Y, DEGOS L: Acutepromyelocytic leukemia. N. Engl. J. Med. (1993) 329:177–189.
   PubMed Web of Science ®Google Scholar
• CUNNINGHAM I, GEE TS, REICH LM, KEMPIN SJ, NAVALAN, CLARKSON BD: Acute promyelocytic leukemia: Treatment results during a decade at Memorial Hospital. Blood (1989) 73:106–112.
   Google Scholar
• STONE RM, MAGUIRE M, GOLDBERG MA et al : Completeremission in acute promyelocytic leukemia despite persistence of abnormal promyelocytes during induction therapy: Experience in 34 patients. Blood (1988) 71:690–696.
   PubMed Web of Science ®Google Scholar
• HUANG ME, YE YC, CHEN SR et al.: Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood (1988) 72:567–572.
   PubMed Web of Science ®Google Scholar
• •Initial report of the efficacy of ATRA in inducing remission in patients with APL establishes the feasibility of differentiation therapy in clinical oncology.
   Google Scholar
• WARRELL RP, JR.: Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid). N. Engl. J. Med. (1991) 324:1385–1393.
   PubMed Web of Science ®Google Scholar
• CASTAIGNE S, CHOMIENNE C, DANIEL MT et al.:All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia. I. Clinical results. Blood (1990) 76:1704–1709.
   PubMed Web of Science ®Google Scholar
• VYAS RC, FRANKEL S AGBOR P et al.: Probing the pathobiology of response to all-trans retinoic acid in acute promyelocytic leukemia: premature chromo-some condensation/fluorescence in situ hybridiza-tion analysis. Blood (1996) 87:218–226.
   Google Scholar
• MENELL JS, CESARMAN GM, JACOVINA BS et al.: Annexin II and bleeding in acute promyelocytic leukemia. N Engl. J. Med. (1999) 340:994–1004.
   PubMed Web of Science ®Google Scholar
• LO COCO F, DIVERIO D, FALINI B et al.: Genetic diagnosis and molecular monitoring in the manage-ment of acute promyelocytic leukemia. Blood (1999) 94:12–22.
   PubMed Web of Science ®Google Scholar
• WARRELL RP, MASLAK P, EARDLEY A et al.: Treatment ofacute promyelocytic leukemia with all-trans retinoic acid: an update of the New York experience. Leukemia (1994) 8:926–933.
   Google Scholar
• MANDELLI F, DIVERIO D, AVVISATI G et al.: Molecular remission in PML/RAlla - positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy. Blood (1997) 90:1014–1021.
   PubMed Web of Science ®Google Scholar
• SHEN Z-X, CHEN G-Q, NI J-H et al.: Use of arsenic trioxide (As203) in the treatment of acute promyelo-cytic leukemia (APL): H. Clinical efficacy and pharma-cokinetics in relapsed patients. Blood (1997) 89:3354–3360.
   Google Scholar
• •Initial report demonstrating the therapeutic effect of arsenic trioxide in 15 patients with relapsed APL.
   Google Scholar
• SOIGNET S, MASLAK P, WANG Z-G et al.: Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N. Engl. J. Med. (1998) 339:1341–1348.
   PubMed Web of Science ®Google Scholar
• SOIGNET S, FRANKEL S, TALLMAN M: US Multicenter Trial of arsenic trioxide (AT) in acute promyelocytic leukemia (APL). Blood (1999) 94\(Suppl. 1):3084 (Abstract).
   Google Scholar
• LALLEMAND-BREITENBACH V, GUILLEMIN M-C, JANIN A et al.: Retinoic acid and arsenic synergize to eradicate leukemic cells in a mouse model of acute promyelo-cytic leukemia. J. Exp. Med. (1999) 189:1043–1052.
   PubMed Web of Science ®Google Scholar
• HE LZ, GUIDEZ F, TRIBOLI C et al.: Distinct interactions of PML-RARa and PLZF-RARa with co-repressors determine differential responses to RA in APL. Nature Genet. (1998) 18:126–135.
   PubMed Web of Science ®Google Scholar
• WARRELL RP, HE L-Z, RICHON V et al.: Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase. J. Natl. Cancer Inst. (1998) 90:124–133.
   PubMed Web of Science ®Google Scholar
• MELO JV: The molecular biology of chronic myeloid leukaemia. Leukemia (1996) 10:751–756.
   PubMed Web of Science ®Google Scholar
• KANTARJIAN HM, O'BRIEN S, ANDERLINI P et al.: Treatment of Chronic Myelogenous Leukemia: Current status and investigational options. Blood (1996) 8:3069–3081.
   Google Scholar
• DRUKER BJ, TALPAZ M, RESTA D et al.: Clinical efficacy and safety of an abl specific tyrosine kinase inhibitor as targeted therapy for chronic myelogenous leukemia. Blood (1999) 94\(Suppl. 1):1639 (Abstract).
   Google Scholar
• •First report of STI-571's ability to induce cytogenetic responses in approximately one third of CML patients in chronic phase who were previously resistant to IFN.
   Google Scholar
• DRUKER BJ, KANTARJIAN H, SAWYERS CL et al.: Activity of an abl specific tyrosine kinase inhibitor in patients with bcr-abl positive acute leukemias in blast crisis. Blood (1999) 94\(Suppl. 1):3082 (Abstract).
   Google Scholar
• HELENE C: Rational design of sequence specific oncogene inhibitors based on antisense and antigene oligonucleotides. Eur. J. Cancer (1991) 27:1466–1471.
   PubMed Web of Science ®Google Scholar
• SZCZYLIK C, SKORSKI T, NICOLAIDES NC et al.: Selective inhibition of leukemia cell proliferation by bcr-abl antisense oligonucleotides. Science (1991) 253:562–565.
   PubMed Web of Science ®Google Scholar
• DE FABRITIIS P, SKORSKI T, DE PROPRIS MS et al.: Effect of bcr-abl oligodeoxynucleotides on the clonogenic growth of chronic myelogenous leukemia cells. Leukemia (1997) 11:811–819.
   Google Scholar
• SKORSKI T, NIEBOROWSKA-SKORSKA M, NICOLAIDES Cet al.: Suppression of Philadelphia 1 leukemia cell growth in mice by bcr-abl antisense oligodeoxynu-cleotide. Proc. Natl. Acad. Sci. USA (1994) 91:4504–4508.
   Google Scholar
• GEWIRTZ AM, LUGAR S, SOKOL D et al.: Oligodeoxynu-cleotide therapeutics for human myelogenous leukemia: interim results. Blood (1996) 270\(Suppl. 1).
   Google Scholar
• HOROWITZ MM, GALE RP, SONDEL PM et al.: Graft-versus- leukemia reactions after bone marrow transplantation. Blood (1990) 75:555–562.
   PubMed Web of Science ®Google Scholar
• MOLLDREM J, DERMIME S, PARKER K et al.: Targeted T-cell therapy for human leukemia: Cytotoxic T lymphocytes specific for a peptide derived from proteinase 3 preferentially lyse human myeloid leukemia cells. Blood (1996) 2450–2457.
   PubMed Web of Science ®Google Scholar
• SMIT WM, RIJNBEEK M, VAN BERGEN CAM et al : Genera-tion of leukemia -reactive cytotoxic T lymphocytes from HLAidentical donors of patients with chronic myeloid leukemia using modifications of a limiting dilution assay. Bone Marrow Transplant (1998) 21:553–560.
   PubMed Web of Science ®Google Scholar
• YOTNDA P, FIRAT H, GARCIA-PONS F et al Cytotoxic T cell response against the chimeric p210 bcr-abl protein in patients with chronic myelogenous leukemia. J. Clin. Invest. (1998) 101:2290–2296.
   PubMed Web of Science ®Google Scholar
• BOCCHIA M, KORONTSVIT T, XU Q et al.: Specific human cellular immunity to bcr-abl oncogene, derived peptides. Blood (1996) 87:3587–3592.
   PubMed Web of Science ®Google Scholar
• PINILLA-IBARZ J, CATHCART K, KORONTSVIT T et al.: Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses. Blood (2000) (In Press).
   Google Scholar
• •This paper reports 50% of APL patients in morphologic CR convert the RT-PCR assay to negative following treatment with an anti-CD33 antibody suggesting activity of the unconjugated monoclonal antibody against minimal residual disease.
   Google Scholar
• TANIMOTO M, SCHEINBERG DA, CORDON-CARDO C etal.: Restricted expression of an early myeloid and monocytic cell surface antigen defined by monoclonal antibody M195. Leukemia (1989) 3:339–348.
   Google Scholar
• SCHEINBERG DA, TANIMOTO M, MCKENZIE S et al.: Monoclonal antibody M195: A diagnostic marker for acute myelogenous leukemia. Leukemia (1989) 3:440–445.
   PubMed Web of Science ®Google Scholar
• SCHEINBERG DA, LOVETT D, DIVGI CR et al.:A Phase ITrial of monoclonal antibody M195 in acute myelogenous leukemia: specific bone marrow targeting and internalization of radionuclide. J. Clin. Oncol. (1991) 9:478–490.
   PubMed Web of Science ®Google Scholar
• SCHWARTZ MA, LOVETT DA, REDNER A et aL:Dose-escalation trial of M195 labeled with iodine 131 for cytoreduction and marrow ablation in relapsed or refractory myeloid leukemias. J. Clin. Oncol. (1993) 11:294–303.
   PubMed Web of Science ®Google Scholar
• PAPADOPOULOS EB, CARON P, CASTRO-MALASPINA H et al.: Results of allogeneic bone marrow transplant following 131I-M195/busulfan/cyclophosphamide in patients with advanced/refractory myeloid malignan-cies. Blood (1993) 82(Suppl.):80a (Abstract).
   Google Scholar
• CARON PC, JURCIC JG, SCOTT AM et al.:A Phase lb trial of humanized monoclonal antibody M195 (anti-CD33) in myeloid leukemia: Specific targeting without inimunogenicity. Blood (1994) 83: 1760-1768.
   Google Scholar
• JURCIC JG, DEBLASIO T, DUMONT L et al.: Molecular remission induction with retinoic acid and anti-CD33 monoclonal antibody HuM195 in acute promyelocytic leukemia. Clin. Cancer Res. (2000) 2:372–380.
   Google Scholar
• STEWART JSW, HIRD V, SNOOK D et cd.:Intraperitoneal yttrium-90-labeled monoclonal antibody in ovarian cancer. J. Clin. Oncol. (1990) 8:1941–1950.
   Google Scholar
• KNOX SJ, GORIS M, BECKER M et a/.:90Y-anti-CD20 monoclonal antibody therapy (IDEC-Y2B8) for recurrent B cell lymphoma./ Immunother. (1994) 16:51 (Abstract).
   Google Scholar
• ROSENBLUM MG, KAVANAGH JJ, BURKE TW et al Clinical pharmacology, metabolism and tissue distribution of 90Y-labeled monoclonal antibody B72.3 after intraperitoneal administration. J. Natl. Cancer Inst. (1991) 83:1629–636.
   Google Scholar
• JURCIC J, DIVIGI CR, MCDEVITT MR et al.: Potential for myeloablation with Yttrium-90-labeled HuM195 (ANTI-CD33): A Phase I trial in advanced myeloid leukemias. Blood (1998) 92\(Suppl. 1):2528 (Abstract).
   Google Scholar
• SIEVERS EL, APPELBAUM FR, SPIELBERGER RT et al.: Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: a Phase I study of an anti-CD33 calicheamicin inimunoconjugate. Blood (1999) 93:3678–3684.
   PubMed Web of Science ®Google Scholar
• SIEVERS E, LARSON R, ESTEY E et al.: Preliminary results of the efficacy and safety of CMA-676 in patients with AML in first relapse. Proc. ASCO(1999) 18:7a (Abstract).
   Google Scholar
• OMARY MD, TROWBRIDGE IS, BATTOFORA HA: Human homologue of murine T-200 glycoprotein. J. Exp. Med. (1980) 152:842–846.
   PubMed Web of Science ®Google Scholar
• MATHEWS DC, APPELBAUM FR, EARY JF et al.: Phase I study of 1311- anti-CD45 antibody plus cyclophospha-mide and total body irradiation for advance acute leukemia and myelodysplastic syndrome. Blood (1999) 94:1237–1247.
   PubMed Web of Science ®Google Scholar
• •This Phase I study demonstrates the feasibility of increasing the radiation dose by conjugating an anti-CD45 antibody to 1311 and incorporating this as part of the conditioning regimen in allogeneic bone marrow transplantation.
   Google Scholar